In 1980, the New England Journal of Medicine published a five-sentence letter to the editor. It was not a study. It had no methodology, no data, and no peer review. The authors, Jane Porter and Hershel Jick, simply noted that out of nearly 12,000 hospital patients treated with narcotics, only 4 became addicted. That letter became the foundation for the most devastating public health crisis in modern American history. Purdue Pharma cited it hundreds of times in marketing materials as proof that opioid addiction was vanishingly rare. The "less than 1%" figure that launched OxyContin traced directly back to those five sentences. The letter's authors later expressed dismay at how their observation had been weaponized. But by then, the damage was measured in hundreds of thousands of bodies. The Launch of OxyContin (1996) Purdue Pharma, owned by the Sackler family, launched OxyContin in 1996. The drug contained oxycodone, a powerful opioid, in a time-release formulation. Purdue's marketing made two extraordinary claims: OxyContin's time-release mechanism made it less addictive than other opioids Fewer than 1% of patients who took it became addicted Both claims were unsupported by rigorous evidence. The time-release mechanism could be easily defeated by crushing and snorting the pill, producing an immediate, heroin-like high. The addiction rate claim was based on the Porter and Jick letter and studies of short-term hospital use that had no relevance to chronic outpatient prescribing. Purdue deployed a sales force of over 1,000 representatives. They targeted doctors in pain management, family medicine, and rural areas -- communities that had limited access to specialist care. Doctors were invited to "pain management seminars" at expensive resorts. They were paid as speakers and consultants. The message was relentless: pain was being undertreated, and OxyContin was the solution. The FDA's Role The FDA approved OxyContin's label with the statement that the drug's "delayed absorption" provided a lower abuse liability than immediate-release opioids. This label claim was critical. It gave Purdue's marketing the appearance of regulatory endorsement. Dr. Curtis Wright, the FDA reviewer who oversaw OxyContin's approval, left the FDA shortly afterward and took a job at Purdue Pharma. The timing drew scrutiny but no formal finding of impropriety. The FDA did not require Purdue to conduct rigorous post-market studies on addiction rates. The agency relied on the company's own data and marketing claims -- data that would later prove to be systematically manipulated. The Body Count The numbers are staggering: 1999-2020: Approximately 841,000 people died from drug overdoses in the United States, with prescription and illicit opioids responsible for over 500,000 of those deaths (CDC) In 2021 alone, over 107,000 Americans died of drug overdoses, the highest annual total ever recorded Opioid overdose deaths were six times higher in 2021 than in 1999 The epidemic has cost the United States an estimated $1.5 trillion in health care, criminal justice, and lost productivity (Council of Economic Advisers, 2019) The crisis evolved in three waves: prescription opioids (1990s-2010), heroin (2010-2016), and synthetic opioids like fentanyl (2016-present). Each wave built on the addiction created by the one before. The 2007 Settlement (And What It Didn't Change) In 2007, Purdue Pharma pleaded guilty to a federal felony for "misbranding" OxyContin by claiming it was less addictive and less subject to abuse than other pain medications. The company paid $634.5 million in fines -- one of the largest pharmaceutical settlements at the time. No individual went to prison. No Sackler family member faced criminal charges. The three executives who pleaded guilty received probation and community service. And Purdue kept selling OxyContin. The 2007 settlement required no changes to the drug's label or marketing. Sales continued to grow. Prescriptions continued to rise. Deaths continued to mount. Internal documents later revealed that Purdue had continued its illegal marketing practices after the 2007 settlement, even as it was under a corporate integrity agreement with the government. The 2020 Guilty Plea and 2021 Bankruptcy In November 2020, Purdue Pharma pleaded guilty to three federal felonies: conspiracy to defraud the United States, conspiracy to violate the Anti-Kickback Statute, and conspiracy to violate the Food, Drug, and Cosmetic Act. The company admitted to paying doctors through speaker programs, directing employees to mislead health care providers, and obstructing the DEA's enforcement efforts. In September 2021, Purdue Pharma was dissolved as part of a bankruptcy settlement. The Sackler family agreed to pay $4.5 billion over time and relinquish control of the company. They were granted civil immunity from future opioid lawsuits -- a provision that remains deeply controversial. The Sackler family had withdrawn approximately $10 billion from Purdue Pharma between 2008 and 2017, even as the death toll mounted. The $4.5 billion settlement represents less than half of what they extracted. The Doctors Who Were Paid Purdue did not act alone. The company built a network of physicians who were paid to prescribe OxyContin and promote it to other doctors. A 2019 study in JAMA Internal Medicine found that pharmaceutical companies paid over $46 million to more than 67,000 physicians for opioid-related marketing between August 2013 and December 2015. Purdue was the largest single payer. Doctors who received opioid-related payments prescribed opioids at significantly higher rates than those who did not. The correlation does not prove causation -- but the pattern is consistent with a strategy of purchasing prescribing behavior. What Was Known, and When The timeline is damning: 1996: OxyContin launches with unsupported addiction claims 1999-2001: Prescription rates surge; early overdose deaths begin climbing 2001: The FDA issues a "public health advisory" about OxyContin abuse -- but does not restrict marketing 2003: The Government Accountability Office reports that Purdue's marketing contributed to abuse and diversion 2007: Purdue pleads guilty; pays $634.5 million; continues marketing 2010: OxyContin is reformulated to make crushing harder; users shift to heroin 2019: Purdue files for bankruptcy as 3,000+ lawsuits converge 2020: Purdue pleads guilty to three felonies 2021: Company dissolved; Sacklers pay $4.5 billion with civil immunity At every point, more was known than was admitted. At every point, the cost of continuing was calculated and found acceptable by the people profiting. They didn't ask if we wanted to know how many deaths were priced into the business model. The number was in the spreadsheets the whole time. _- The Department_